Fellows Poster

(8-001) Assessing a National GPO’s Sourcing Evaluation of Supply Reliability: A Retrospective Review of Product Backorder Incidence

(8-002) Evaluating the Effect of a Global Holiday Calendar on Faculty Scheduling

(8-003) Pharmacy-Led Strategies to Advance Diversity in Sickle Cell Disease Clinical Trials: A Policy and Practice Literature Review

(8-009) Comparative Effectiveness of Once-weekly Basal Insulins vs. Daily Glargine in Type 2 Diabetes: a Bayesian Meta-Analysis of Randomized Trials

(8-010) Empowering Pharmacists in Cognitive Health: the Alzheimer's Disease Continuum and Dementia Risk Reduction

(8-011) Factors and Disparities Influencing Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide 1 Receptor Agonists Initiation in the United States: A Scoping Review of Evidence

(8-015) Comparative Safety and Effectiveness of Antiplatelet Regimens After Transcatheter Aortic Valve Implantation in Patients with Coronary Artery Disease

(8-016) Health Outcomes of Guideline-directed Medical Therapy for Heart Failure in Patients with Transthyretin Amyloid Cardiomyopathy

(8-021) Beyond Patient Factors: How Formulation Acceptability Predicts Adherence to Calcium–Vitamin D

(8-022) Management of Systemic Anti-Cancer Therapy in an Integrated Oncology Clinic versus Conventional Oncologist Consultation: A Retrospective and Observational Study in a Hong Kong Hospital

(8-026) Beyond the Skin: Exploring Comorbidities in Hidradenitis Suppurativa Patients

(8-027) Boxed Warnings in FDA Drug Approvals, 2022–2024: Do Safety Risks Cluster Within Certain Therapeutic Areas?

(8-028) Evaluating Clinical Pharmacist Interventions in a Tertiary Care Hospital: A Retrospective Study from Saudi Arabia

(8-029) From Discovery to Delivery: Addressing Access Challenges for Cell and Gene Therapy

(8-030) Real-World Effectiveness of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatments: A Retrospective Electronic Health Record Analysis of Liver Enzymes and Cardiometabolic Outcomes

(8-033) Assessing Availability of Buprenorphine/Naloxone Films in Illinois Community Pharmacies Post X-Waiver Removal: A Secret Shopper Survey

(8-034) Learner-Led Preventive Health Education for Formerly Incarcerated Individuals

(8-038) Evaluating the Safety and Efficacy of Psilocybin for the Treatment of Post-Traumatic Stress Disorder

(8-040) Physical-Chemical Stability Analysis of Droperidol Using High-Resolution Liquid Chromatography for Use in Kiro Fill

(8-043) Fibrates for primary biliary cholangitis: effectiveness, safety, and cost-minimization of an off-label treatment protocol in real-world clinical practice

(8-044) Long-Term Real-World Effectiveness and Safety of Mepolizumab in Patients with Uncontrolled Severe Asthma

(8-045) Oral Ondansetron as an Over-the-Counter Medication: Safety First, Aisle Second

(8-046) Showcasing the Value of Medical and Clinical Content on Medical Information Sites by Pharmaceutical Companies for Healthcare Professional Use

(8-047) Therapeutic Peptides: A Sword that Cuts Both Ways

(8-048) Treating Maternal Pain, Protecting Fetal Brain? A Review of Acetaminophen Use in Pregnancy

(8-062) Diversity and Representation in US-Based Phase 3 HIV Clinical Trials: A Literature Review

(8-063) From Shortage to Stewardship: Rational Use of Aztreonam in a Tertiary Hospital

(8-064) Racing against time: impact of antibiotic administration, prescription and validation times on outcomes in the sepsis code

(8-077) AI and Automation Innovations for Streamlining Workflows and Enhancing Efficiency in Clinical Trials

(8-078) Artificial Intelligence (AI) Accuracy in Healthcare: Identifying Misinformation in Migraine Therapeutics

(8-079) Artificial Intelligence (AI) and Large Language Model (LLM) Adoption in Biopharma: A Structured Literature Review of Use Settings, Implementation Challenges, and Regulatory Governance

(8-080) Artificial Intelligence vs Human-Derived Safety Evaluations in Advanced Prostate Cancer: Concordance Across Randomized Controlled Trials, Real-World Evidence, and Patient-Reported Outcomes

(8-081) Concordance Between Artificial Intelligence (AI) and Human-Derived Analysis: Drug-Drug Interactions Between Direct Oral Anticoagulants (DOACs) and Androgen Receptor Pathway Inhibitors (ARPIs)

(8-082) Evaluating the Impact of Automation on Safety, Efficiency, and Costs in Oncology Pharmacy: A Multi-Study Analysis

(8-088) Artificial Intelligence in Medical Affairs: Opportunities, Challenges, and the Pharmacist’s Role

(8-089) Impact on FDA’s Real-Time Oncology Review (RTOR) Program on Drug Labeling: Streamlining the Path to Patient Access

(8-090) Investigating the Impact of GLP-1–Based Medical Weight Loss on Facial Aesthetics and the Potential Role of Dermal Fillers

(8-091) Strategic Response to Market Disruption: The Syfovre Case and Post-Launch Volatility in Biopharmaceutical Commercialization

(8-092) Streamlining Biosample Collection: Prospective Assessment of Patient-centric Low-Volume Smart Testing Devices in Healthy Volunteers

(8-094) Adeno-Associated Virus Gene Therapies: Trends, Therapeutic Areas, and Clinical Development

(8-095) Best Practices on Labeling Investigational Injectable Products

(8-096) CLX-155A: Preclinical Evaluation of a Novel Oral 5-FU and Valproic Acid Prodrug for Triple-Negative Breast Cancer in a Nude Mouse Xenograft Model

(8-097) Comprehensive Review of Immunotherapeutic Mechanism of Actions in Pancreatic Cancers

(8-098) Design and Methodology of Post-Hoc Analyses to Assess Hospitalizations across the Efsitora QWINT T2D Phase 3 Clinical Trials

(8-099) Developing a Patient-Centered Model to Enhance Patient Experience in Clinical Trials at the Pharmacy Service of Hospital General Universitario Gregorio Marañón

(8-100) Genetic Diversity and Market Growth: Advancing Clinical Trial Representation in Africa

(8-101) Trends in Patient-Reported Outcome Measures (PROMs) in Phase 2 and 3 Pulmonary Arterial Hypertension (PAH) Clinical Trials from 1998 to 2025

(8-107) Analysis of Immune-Related Adverse Events in a Diverse Patient Population with Advanced Non-Small Cell Lung Cancer

(8-108) Emerging Biomarkers in Breast Cancer: Translating Discovery into Personalized Medicine

(8-109) Exploring Barriers to African American Adults’ Participation in Colorectal Cancer Clinical Trials

(8-110) Incidence of White Blood Cell Toxicity and Infections in Patients Treated with Trifluridine/Tipiracil Plus Bevacizumab in Real-World Practice

(8-111) Interactions matter: lessons from sarcoma patients in real life

(8-112) LIBERTAS: Assessing the Impact of Intermittent vs. Continuous ADT via Implementation of Endpoints Derived From Digital Wearables in Patients with Castration Sensitive Prostate Cancer

(8-113) Liposomal Formulations in the Management of Newly Diagnosed Transplant-Eligible Multiple Myeloma

(8-114) Optimization of Patient Recruitment in Clinical Trials through Artificial Intelligence Integration (TrialGPT Project)

(8-115) Pharmacogenomic Predictors of Immunotherapy Response and Toxicity in Cancer Treatment

(8-116) Real-World Analysis of Time-of-Day Administration of Immune Checkpoint Inhibitors

(8-117) Real-world Experience of Acute Myeloid Leukemia (AML) Treatment in Elderly – Evaluation of Prescribing Patterns and Survival Outcomes

(8-118) Real-World Utilization of PSMA-PET Imaging in Prostate Cancer: Insights from an Integrated U.S. Health System

(8-119) Regulatory Pathways and Timelines for Hematology and Oncology Drug Approvals in the United States Over the Past Decade

(8-120) Regulatory Pathways for Rare Oncology Approvals with FDA vs. EMA

(8-123) Estimating Direct and Indirect Health Utility Weights Among Pregnant, Postpartum, and Recently Miscarried Women with Opioid Use Disorder: Preliminary Findings

(8-125) Implementation of a Pediatric Stratification Model Developed by the Spanish Society of Hospital Pharmacy

(8-126) Real-world outcomes of letermovir use in pediatric hematopoietic stem cell transplant recipients

(8-127) Contribution of Microbiome-Derived Drug Metabolism to Interindividual Variability in the Pharmacokinetics of Duloxetine

(8-128) Pharmacogenomic-based monthly medication reviews in a diverse sample of long-term care residents across the United States: a descriptive analysis

(8-129) Preventing Medication Harm: Cost-effectiveness of Regional Pharmacogenetics Implementation

(8-133) Analysis of a Decade of FDA Guidance: Yearly Trends in Volume, Type, and Regulatory Focus from 2016-2025

(8-134) Bridging the Gap: Standardizing 340B Community Benefit Statements to Drive Impactful Health Outcomes

(8-135) Global Regulatory Alignment and the Role of AI, Lessons from FDA, EMA, WHO, and the African Medicines Agency

(8-136) Mapping Stakeholder Impacts of the 340B Drug Pricing Program: A Systematic Review and Conceptual Framework

(8-137) Operationalizing Real‑World Evidence for Regulatory Submissions and Pharmacovigilance

(8-138) Revolutionizing Patient Screening: A Global Regulatory Framework for AI/ML-Driven Patient Screening in Clinical Trials

(8-139) Uncovering Regulatory Affairs CMC Trends in FDA Complete Response Letters (CRLs): A Data Mining Analysis of Over 200 CRLs to Inform Regulatory Strategy

(8-142) Assessing Artificial Intelligence Competency: A Survey of Knowledge, Confidence, and Willingness to Learn Among Pharmacy Preceptors

(8-143) Building Oncology Pharmacy Capacity in Sub-Saharan Africa: A Descriptive Evaluation of a Resident-Led Training Initiative in Cancer Therapeutics

(8-144) Comparison of summative Objective Structured Clinical Examination (OSCE) performance in P3 pharmacy students with and without a formative OSCE

(8-145) Retrospective Review of Scholarship Activities Conducted by Biopharmaceutical Industry PharmD Fellows

(8-146) To License or Not to License: Trends and Factors Influencing Pharmacy Fellows’ Decisions

(8-149) Analysis of 2024 PharmD Industry Fellowship Outcomes

(8-150) Bridging the Gap: Assessing the Value and Industry Perception of PharmD Fellowships in Biopharmaceutical Careers

(8-151) Evaluating the Impact of Infectious Disease Continuing Education: A Comparative Analysis of Pharmacist Engagement, Knowledge, and Confidence Across 2024 and 2025 Educational Initiatives

(8-152) Evaluation of Pharmacy Licensure Rates Among The Rutgers Pharmaceutical Industry Fellowship Program

(8-153) Medical Affairs: A Key Partner Driving Clinical Trial Success

(8-154) Valued or Overvalued? Unpacking the MBA’s True Worth in the Eyes of Industry Pharmacists and Pharma Leaders.

(8-157) Cost-Effectiveness and Budget-Impact Evidence for Long-Acting Injectable Antipsychotics in Maintenance Treatment of Bipolar I Disorder

(8-158) EARLY PHARMACY-LED MEDICATION RECONCILIATION IMPROVES LEVODOPA SCHEDULING AND REDUCES MEDICATION ERRORS IN PARKINSON’S DISEASE

(8-159) Uncovering Disparities in Alzheimer’s Disease Research: A Comparison of Clinical Trial Demographics and U.S. Epidemiological Data

(8-165) Comparative Analysis of Community Engagement in Clinical Research Organizations To Advance Inclusive Clinical Trials

(8-166) From Awareness to Action: Addressing Health Care Disparities Through Evidence-Based Community Initiatives

(8-167) Off the grid, on the meds: a mobile approach to hypertension control in underserved and unhoused populations

(8-168) Preferred Terminology of Individuals Who Engage with Harm Reduction and Medications for Opioid Use Disorder Services

(8-169) Role of Demographic Representation in Shaping Clinical Trial Development

(8-170) Societal Taboos, Public Perceptions of Different Types of Pain, and The Impact on Seeking Pain Relief

(8-171) Socioeconomic Disparities in Adult Sleep Health: Progress Toward Healthy People 2030 Goals

(8-172) The global burden of mental and substance use disorders among adolescents and young adults

(8-173) United States vs European Union: A Comparative Study of COVID-19 Mortality Patterns

(8-177) Cannabis Use Documentation Within the Electronic Health Record Over a 9.5-Year Period: Exploration of Factors Influencing Cannabis Documentation

(8-178) Evaluation of High-Risk Medication Use in Fall-Related Emergency Department Visits in Older Adults

(8-179) Implementation of a Scalable, System-Wide Education and Compliance Strategy for REMS Programs Across a Multi-Hospital Health System

(8-186) Real-World Insights into Strategies Used to Support Health Literacy in Specialty Pharmacy

(8-188) Acceptability of a Mobile App for Passive Monitoring of Quality of Life and Functional Capacity in Patients with Colorectal Cancer

(8-189) Digital transformation of HIV pharmacotherapeutic care: impact of a mobile monitoring app

(8-192) A Multi-State Survey of Recovery Program Access for the Full Pharmacy Workforce

(8-193) Mapping the Landscape of Impostor Syndrome in Pharmacy: A Literature Review of Current Evidence

(8-197) Efficacy and safety of lidocaine compared to other pharmacologic agents for intrauterine device (IUD) insertion pain: systematic review and meta-analysis

(8-198) Systematic Review of FDA Approved Biologics (Dupilumab, Nemolizumab, Tralokinumab, and Lebrikizumab) Use for ​ Moderate-to-Severe Atopic Dermatitis in Pregnancy

(8-199) Global Harmonization and Digital Transformation in Regulatory Affairs: A Literature Review of Emerging Trends and Challenges in 2025

(8-200) Improving Health Literacy Practices: Insights from Surveying Acute Care and Specialty Pharmacy Staff

(8-201) Strategic Imperatives for Integrated Evidence Generation Across Functional Domains in Biopharmaceutical Development